Insights from 2023 ESMO Annual Meeting
Playback speed
10 seconds
ESMO 2023 Insights: "Randomized Phase 3 GASTFOX Study - 5-fluorouracil & Oxaliplatin +/- Docetaxel in the 1L Treatment of HER2- Locally Advanced Unresectable/Metastatic Gastric/GEJ Adenocarcinoma"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Aziz Zaanan
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Aziz Zaanan
386 views
October 26, 2023
Comments 0
Login to view comments.
Click here to Login
Gastrointestinal